Founded in 2014 by three experienced individuals, ABCDx combines expertise in biomarker discovery, validation, and clinical experience to develop a device that analyzes the level of proteins in the blood using a single drop of blood. The device diagnoses the probability of a mild traumatic brain injury within ten minutes, enabling healthcare professionals to make quick clinical decisions and significantly lower expenses for the majority of patients. This innovative technology has the potential to revolutionize the diagnosis and treatment of mild traumatic brain injuries.